Welcome to VALENCIA TOWN CENTER PHARMACY

Serving the Santa Clarita Valley since 2005

Xifaxan 550 mg (Rifaximin): Brand Product, Generic Approval and Availability

Xifaxan is the U.S. brand name for rifaximin. Current DailyMed labeling identifies Xifaxan 550 mg tablets as a prescription drug distributed by Salix Pharmaceuticals, a division of Bausch Health US. The product is not over the counter.

This page requires an additional distinction that is especially important in 2026: an FDA-approved generic can exist before that generic is commercially available for routine pharmacy dispensing.

Xifaxan 550 mg is the branded rifaximin product

Current DailyMed labeling lists Xifaxan 550 mg tablets under NDA 021361. Each 550 mg tablet contains rifaximin, and the package label states "Rx only." The same brand also has a 200 mg tablet, but the two strengths have different labeled uses and should not be treated as interchangeable.

For a prescription specifically written for Xifaxan 550 mg, patients should verify the strength and whether the prescription is intended as brand-only or permits substitution when an appropriate generic is actually available and legally marketable.

FDA approved an Actavis generic in March 2026

On March 19, 2026, FDA approved Actavis Laboratories FL, Inc. ANDA 208959 for rifaximin tablets, 550 mg. FDA's approval letter states that the Actavis product is bioequivalent and therapeutically equivalent to the reference listed drug, Xifaxan 550 mg.

That is a final FDA approval, not a tentative approval. It is therefore inaccurate, as of October 2026, to say that no generic rifaximin 550 mg product has ever received final FDA approval.

However, FDA approval does not by itself prove that the generic is currently on pharmacy shelves.

Approval is not the same as commercial market availability

Bausch Health and Salix announced the Actavis settlement on September 12, 2018. Under the agreement, Actavis received a non-exclusive license effective January 1, 2028 to intellectual property covering Xifaxan 550 mg in the United States. The company announcement also expressly allows earlier entry under a specified condition: Actavis may begin marketing earlier if another generic rifaximin product is approved and begins selling or distributing before January 1, 2028.

Accordingly, the careful current statement is: an Actavis generic rifaximin 550 mg has final FDA approval, but final approval does not establish current commercial availability. The 2018 settlement sets January 1, 2028 as the licensed entry date while permitting earlier entry under the stated condition, so January 1, 2028 should not be described as an unconditional earliest possible launch date.

Other rifaximin ANDAs have also received tentative approval, but tentative approval should not be represented as final approval or proof of current market availability.

What a patient should verify at the pharmacy

For a current Xifaxan 550 mg prescription, the practical questions are whether the prescription is for the branded product, whether an actually marketable equivalent is available at the time of filling, what the pharmacy's wholesaler can supply, and how the insurance plan covers the product.

Because a branded prescription product can be expensive, formulary and prior-authorization rules may materially affect access. A rejected claim can arise from plan restrictions, prior authorization, quantity rules, pharmacy network or other benefit design. A pharmacist can identify the rejection message, but the insurer or prescriber may need to resolve clinical authorization.

Patients should be cautious with websites that advertise "generic Xifaxan" without identifying the manufacturer, U.S. approval status and actual market status. An ANDA number, tentative approval or overseas product listing is not the same thing as a U.S. generic that a pharmacy can legally purchase and dispense today.

Prescription status and safe product research

Rifaximin 550 mg remains prescription-only. The strength should not be used to infer an individualized treatment regimen, and this page does not provide dosing instructions. The correct product and regimen depend on the prescribed indication and the clinician's directions.

Why this distinction matters for price comparisons

A price-comparison page may display a "generic" label before a generic is practically purchasable through ordinary U.S. pharmacy channels. For Xifaxan 550 mg in 2026, that can produce a misleading impression because final FDA approval and licensed launch timing are separate facts.

Before relying on a quoted generic price, a patient should ask what manufacturer and NDC the quote refers to and whether the pharmacy can actually order that product today. If the answer is only that an ANDA has been approved, that is not enough to establish current supply. Until a generic is lawfully marketed and obtainable, insurance and cash-price discussions may still center on the branded Xifaxan product.

For broader medication and pharmacy information, see Medication & Pharmacy Resources.

Contact Valencia Town Center Pharmacy at (661) 291-1800 to ask about Xifaxan prescription requirements, current availability of the branded 550 mg product, insurance/formulary questions, and whether any lawfully marketable equivalent is available at the time of the prescription.

Go to purchase

trusted supplier